Earnings Releases·Nov 5, 2026, 4:13 PM ET

Eton Pharmaceuticals — Third Quarter 2026 Earnings Summary

Q3 2026 net revenue surged 158% YoY to $57.9 million, with GAAP net income turning positive at $35.2 million ($1.06/share) versus a $1.9 million loss in the prior year period.
Raised full-year 2026 revenue guidance to over $175 million and Adjusted EBITDA margin guidance to over 40%, citing record active patient counts across all key products and the September launch of IMPAVIDO.
Executed strategic expansion by acquiring U.S. rights to ASN-001 for $3 million and securing an exclusive license for LIBERVANT, with LIBERVANT launch anticipated in April 2027 and ASN-001 NDA submission expected in 2027.
Cash position strengthened to $55.6 million as of September 30, 2026, while G&A expenses rose 98% YoY to $16.0 million due to higher stock-based compensation, headcount, and FDA fees following the loss of orphan drug fee exemption eligibility.